Letter to the editor concerning “Single-institution experience of performing bloodless transplant in Jehovah’s Witness patients” by Coltoff A, Aditya S, Solmaz A, and Steinberg A. (Hematol oncol stem cell ther 2019;12(1):44–9.)
Publication date: Available online 11 October 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Jennifer C. Zhao, Justin R. Arnall, Allison L. Martin, Saad Usmani, Shebli Atrash (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 31, 2019 Category: Cancer & Oncology Source Type: research

Ten-year survival outcomes for patients with early stage classical Hodgkin lymphoma: An analysis from Kentucky Cancer Registry.
ConclusionWhile radiation therapy might increase long-term toxicity in cHL, in our large data cohort, radiotherapy consolidation as part of the initial therapy for early stage disease provides superior survival at 10 years, especially in favorable risk cHL. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 29, 2019 Category: Cancer & Oncology Source Type: research

High-Dose Intravenous Methotrexate in the Management of Breast Cancer with Leptomeningeal Disease: Case Series and Review of the Literature
Publication date: Available online 14 October 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Jonathan T. Kapke, Robert J. Schneidewend, Zeeshan A. Jawa, Chiang-Ching Huang, Jennifer M. Connelly, Christopher R. Chitambar (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 15, 2019 Category: Cancer & Oncology Source Type: research

How a Population-based Analysis Compares to Clinical Trials in Early Stage Classical Hodgkin Lymphoma
ConclusionWhile radiation therapy might increase long-term toxicity in cHL, in our large data cohort, radiotherapy consolidation as part of the initial therapy for early stage disease provides superior survival at 10 years, especially in favorable risk cHL. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 15, 2019 Category: Cancer & Oncology Source Type: research

Outcomes of High-Risk Acute Promyelocytic Leukemia patients Treated with Arsenic Trioxide (ATO)/All Trans Retinoic Acid (ATRA) Based Induction and Consolidation Without Maintenance Phase
We present a retrospective analysis of 10 patients that were treated for high risk APL based on the consolidation treatment phase of APL 0406 study without subsequent maintenance. With a median follow up of 38 months, all patients remain in remission. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 15, 2019 Category: Cancer & Oncology Source Type: research

Comparative Effectiveness of Busulfan/Cyclophosphamide versus Busulfan/Fludarabine Myeloablative Conditioning for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome
ConclusionWe confirmed that myeloablative Bu/Flu conditioning has comparable clinical and QOL outcomes to Bu/Cy. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 12, 2019 Category: Cancer & Oncology Source Type: research

The AUGMENT Study: Lenalidomide in Indolent Lymphoma … Balance the Imbalance!
Publication date: Available online 11 October 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Reyad Dada (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 12, 2019 Category: Cancer & Oncology Source Type: research

Letter to the Editor concerning “ Single-institution experience of performing bloodless transplant in Jehovah’s Witness patients” by Coltoff A, Aditya S, Solmaz A, and Steinberg A. (Hematol Oncol Stem Cell Ther 2019;12(1):44–9.)
Publication date: Available online 11 October 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Jennifer C. Zhao, Justin R. Arnall, Allison L. Martin, Saad Usmani, Shebli Atrash (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 12, 2019 Category: Cancer & Oncology Source Type: research

The Role of Recombinant Human Erythropoietin in Neonatal Anemia
This study was carried out on 80 neonates divided into; group I (30 preterm neonates) with AOP received EPO (250 IU/kg/dose subcutaneously 3 times weekly for 4 weeks), compared to group II (30 neonates) with AOP treated only with blood transfusion; Group III(10 neonates, GA ≥ 37 weeks) with late hypo-regenerative post haemolytic anemia, treated with the same dose of r-Hu EPO and compared to group IV (10 neonates) treated only with blood transfusion. Hematological measurements and transfusion requirements were followed during therapy. Serum level of EPO was measured by ELISA technique.ResultsBy the end of the 4th week of...
Source: Hematology Oncology and Stem Cell Therapy - October 12, 2019 Category: Cancer & Oncology Source Type: research

Synchronous Multiple Myeloma and Gaucher Disease
Publication date: Available online 9 October 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Jorge Monge, Amy Chadburn, Usama GergisAbstractPseudo-Gaucher cells can be found in multiple hematologic malignancies, hemoglobinopathies, infections, and multiple storage disorders upon bone marrow aspirate and biopsy; however, Gaucher disease (GD) should be ruled out, particularly when the cytoplasmic inclusions cannot be adequately characterized. It is well known that GD may be associated with monoclonal gammopathies; however, although enzyme replacement therapy (ERT) may result in an improvement in polyclonal ga...
Source: Hematology Oncology and Stem Cell Therapy - October 10, 2019 Category: Cancer & Oncology Source Type: research

Clinical Predictors of Delayed Engraftment in Autologous Hematopoietic Cell Transplant Recipients
Publication date: Available online 10 October 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Forat Lutfi, William Paul Skelton, Yu Wang, Emma Rosenau, Nosha Farhadfar, Hemant Murthy, Christopher R. Cogle, Ranadall Brown, John Hiemenz, John Hiemenz, John R. Wingard, Maxim NorkinAbstractObjective/BackgroundClinical predictors of delayed engraftment following autologous hematopoietic cell transplantation (AHCT) are poorly described in the literature. The purpose of this study was to identify pretransplant characteristics contributing to delayed engraftment (DE) following AHCT.MethodsA retrospective, single in...
Source: Hematology Oncology and Stem Cell Therapy - October 10, 2019 Category: Cancer & Oncology Source Type: research

The Effects of Granulocyte Colony-Stimulating Factors (G-CSFs) in Leucocytes
We present a case report of a 29-year-old woman where these laboratory findings are described. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 10, 2019 Category: Cancer & Oncology Source Type: research

Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond
Publication date: Available online 20 August 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Marcelo C. Pasquini, Alok Srivastava, Syed Osman Ahmed, Mahmoud Aljurf, Yoshiko Atsuta, Carol Doleysh, Sebastian Galeano, Eliane Gluckman, Hildegard Greinix, Gregory Hale, Parameswaran Hari, Shahrukh K. Hashmi, Naynesh Kamani, Mary J. Laughlin, Dietger Niederwieser, Adriana Seber, Jeffrey Szer, John A. Snowden, Koen Van Biesen, Paula WatryAbstractHematopoietic cell transplantation (HCT) is a highly complex procedure that requires a dedicated multidisciplinary team to optimize its safety. In addition, institutions ma...
Source: Hematology Oncology and Stem Cell Therapy - August 21, 2019 Category: Cancer & Oncology Source Type: research

Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): clinical, technical and socio-economic considerations
This report describes recommendations from the Worldwide Network for Blood and Marrow Transplantation (WBMT) for establishing HSCT programs with a specific focus on developing countries, and identifies challenges and opportunities for providing this specialized procedure in the resource constrained setting. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - August 21, 2019 Category: Cancer & Oncology Source Type: research

Autologous Stem Cell Transplantation may be Curative for Patients with Follicular Lymphoma with Early Therapy Failure without the need for Immunotherapy
Publication date: Available online 9 July 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Ana Jiménez-Ubieto, Carlos Grande, Dolores Caballero, Lucrecia Yáñez, Silvana Novelli, Miguel Teodoro Hernández-Garcia, María Manzanares, Reyes Arranz, José Javier Ferreiro, Sabela Bobillo, Santiago Mercadal, Andrea Galeo, Javier López Jiménez, José M. Moraleda, Carlos Vallejo, Carmen Albo, Elena Pérez, Carmen Marrero, Laura Magnano, Luis PalomeraAbstractBackgroundPatients with follicular lymphoma (FL) with early therapy failure (ETF) within 2 years ...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2019 Category: Cancer & Oncology Source Type: research

Splenic Marginal Zone Lymphoma Associated with Hepatitis B Virus Infection, Remission after Viral Treatment, and Splenectomy: A Case Report and Review of the Literature
We report the case of a patient diagnosed with a splenic marginal zone lymphoma with a simultaneous finding of hepatitis B virus infection, who responded to antiviral treatment and splenectomy. We highlighted this association described in the literature and its possible causal role, as well as the available therapeutic choices. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2019 Category: Cancer & Oncology Source Type: research

Cytokine Release Syndrome and Neurologic Toxicities Associated with Chimeric Antigen Receptor T-Cell Therapy: A Comprehensive Review of Emerging Grading Models
Publication date: Available online 10 June 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Julio C. Chavez, Michael D. Jain, Mohamed A. Kharfan-DabajaAbstractAdvances in the fields of immuno-oncology and T-cell engineering have brought autologous chimeric antigen receptor T-cell (CART) therapies from the bench to the bedside. At present, two CART products that target CD19 are commercially available: tisagenlecleucel and axicabtagene ciloleucel. They have demonstrated remarkable efficacy for their particular indications. One challenge is to compare the safety among commercially available and clinical trial C...
Source: Hematology Oncology and Stem Cell Therapy - June 11, 2019 Category: Cancer & Oncology Source Type: research

Bortezomib for Immune Thrombocytopenia and Autoimmune Hemolytic Anemia
Publication date: Available online 10 June 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Ibrahim N. Muhsen, Ali Alahmari, Mohammed Alnahedh, Nora A. Alkhudair, Hadeel Samarkandi, Riad El Fakih (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - June 11, 2019 Category: Cancer & Oncology Source Type: research

Extramedullary Hematopoiesis Occurring as a Gastric Polyp in a Woman with a Myeloproliferative Disorder
Publication date: Available online 10 June 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Badr AbdullGaffar, Sharifa Karam, Basam Odeh (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - June 11, 2019 Category: Cancer & Oncology Source Type: research

Special Report: Summary of the First Meeting of African Blood and Marrow Transplantation (AfBMT) Group, Casablanca, Morocco, April 19–21, 2018 held under the auspices of the Worldwide Network for Blood and Marrow Transplantation (WBMT)
Publication date: Available online 4 June 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Mhamed HarifAbstractThe first meeting of the African Blood and Marrow Transplantation (AfBMT) was held in Casablanca from April 19, 2018 to April 21, 2018, with the aim of fostering hematopoietic stem cell transplantation (HSCT) activity in Africa. Out of the 54 African countries, HSCT is available only in six (Algeria, Egypt, Morocco, Nigeria, South Africa, and Tunisia). During this meeting, African teams and international experts from the Worldwide Network for Blood and Marrow Transplantation (WBMT) gathered to share...
Source: Hematology Oncology and Stem Cell Therapy - June 4, 2019 Category: Cancer & Oncology Source Type: research

Epidemiological, Clinical, and Severity Characterization of Sickle Cell Disease in a Population from the Brazilian Amazon
ConclusionOur results represent the first comprehensive characterization of epidemiological, laboratorial, and clinical data of SCD in the region of the Brazilian Amazon. Despite the higher contribution of Amerindian ancestry previously demonstrated in this region, the main clinical characteristics of SCD seem similar to those reported in other populations. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - May 29, 2019 Category: Cancer & Oncology Source Type: research

Updates in Prognostication and Treatment of Waldenström’s Macroglobulinemia
Publication date: Available online 28 May 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Pooja Advani, Aneel Paulus, Sikander AilawadhiAbstractWaldenström’s macroglobulinemia (WM) is a rare, incurable hematologic disorder with a relatively indolent course in a majority of the patients. Despite this, a significant proportion of patients require treatment because of hypersecretion of immunoglobulin M and the invasion of bone marrow and peripheral organs by neoplastic lymphoplasmacytic lymphoma cells. Historically, there has been a dearth of research and therapeutic advancements in the field of WM,...
Source: Hematology Oncology and Stem Cell Therapy - May 29, 2019 Category: Cancer & Oncology Source Type: research

Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia With an e14a3 BCR-ABL1 Fusion: The Role of Molecular Monitoring
Publication date: Available online 28 May 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Mireille Crampe, Stephen E. Langabeer, David O'Brien, Eileen Ryan, C. Larry Bacon (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - May 29, 2019 Category: Cancer & Oncology Source Type: research

Updates in Prognostication and Treatment of Waldenström’s Macroglobulinemia
Publication date: Available online 29 May 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Pooja Advani, Aneel Paulus, Sikander AilawadhiAbstractWaldenström’s macroglobulinemia (WM) is a rare, incurable hematologic disorder with a relatively indolent course in a majority of the patients. Despite this, a significant proportion of patients require treatment because of hypersecretion of immunoglobulin M and the invasion of bone marrow and peripheral organs by neoplastic lymphoplasmacytic lymphoma cells. Historically, there has been a dearth of research and therapeutic advancements in the field of WM,...
Source: Hematology Oncology and Stem Cell Therapy - May 29, 2019 Category: Cancer & Oncology Source Type: research

Isoderivative chromosome 17 with multiple copies of RARα–PML fusions and Tp53 deletion in a rare case of APML
We report a case of adult APML with amplification of RARα/PML fusion protein, a consequence of isoderivative 17 with duplication of normal chromosome 15 and 17 and Tp53 deletion on derivative 17. Immunophenotyping by flow cytometry, presence of pancytopenia and epistaxis helped classify the patient as APML. FISH was used for confirmation of the same and indicated involvement of additional abnormalities. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - April 21, 2019 Category: Cancer & Oncology Source Type: research

Isoderivative Chromosome 17 With Multiple Copies of RARA–PML Fusions and Tp53 Deletion in a Rare Case of APML
Publication date: Available online 6 April 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Dhanlaxmi Shetty, Elizabeth Talker, Manju Sengar, P.G. Subramanian (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - April 7, 2019 Category: Cancer & Oncology Source Type: research

Intraocular Involvement of Mantle Cell Lymphoma: A Case report and Literature review
Publication date: Available online 6 April 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Madiha Iqbal, Yennifer Gil Castano, Taimur Sher, Mohamed A. Kharfan-DabajaAbstractLymphomatous involvement of the ocular adnexal region (OAR) is generally rare; however, it constitutes the most common ocular malignancy. Most cases of ocular adnexal lymphomas are extra nodal marginal zone B cell lymphomas. Mantle cell lymphoma involvement (MCL) of the OAR is a less common presentation compared with other lymphomas and it has been reported anecdotally. Studies have suggested an association of OAR involvement with poor p...
Source: Hematology Oncology and Stem Cell Therapy - April 7, 2019 Category: Cancer & Oncology Source Type: research

Splenectomy Following JAK1/JAK2 Inhibitor Therapy in Patients With Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation
ConclusionSplenectomy before alloHSCT might be a promising option in patients who failed to achieve significant spleen response after ruxolitinib therapy. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - April 7, 2019 Category: Cancer & Oncology Source Type: research

Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years
We report our institutional experience with HSCT in patients aged ≥70 years. A cohort of 22 patients underwent HSCT. Median overall survival was 5.16 years [95% confidence interval (CI): 1.5–8.7 years], and median post-transplant survival was 2.2 years (myelodysplastic syndrome: median 1.3 years, 95% CI: 4.7 months–2.2 years; acute myeloid leukemia: median not reached). Thirty-day mortality following transplantation was 9.5% (n = 2). These data provide further support for the use of transplantation in selected older patients, and highlight the impact of HSCT on overall survival among a pati...
Source: Hematology Oncology and Stem Cell Therapy - March 4, 2019 Category: Cancer & Oncology Source Type: research

The Prevalence and Prognostic Significance of Autoimmune Cytopenias in a Cohort of Egyptian Patients With Chronic Lymphocytic Leukemia
ConclusionWe have shown a prevalence of 11.8% for AIC among our CLL patients. AIC was associated with unsatisfactory normalization of the hematological parameters even with therapy and lower number of patients with CLL downstaging in comparison with patients without AIC. These results suggest that AIC is a fingerprint of a biologically more aggressive disease even if no significant impact on overall survival was found. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - February 21, 2019 Category: Cancer & Oncology Source Type: research

Phenotypic Characterization of Malignant Progenitor Cells in Patients with Idiopathic Myelofibrosis
ConclusionThese data indicate that IL-3Rαhigh CD34+ cells from IM enriched for the malignant progenitor cells and IL-3Rα/CD123 may be a potential biomarker and therapeutic target for IM. Our findings will be further validated in future studies with a larger sample size and serial transplant in murine models. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - February 21, 2019 Category: Cancer & Oncology Source Type: research

Graft-Versus-Host Disease of the Kidney
Publication date: Available online 20 February 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Abhilash Koratala, Mark S Segal, Nosha Farhadfar, Xu Zeng (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - February 21, 2019 Category: Cancer & Oncology Source Type: research

Prediction of Oncotype Dx Recurrence Score Using Clinical Parameters: A Comparison of Available Tools and a Simple Predictor Based on Grade and Progesterone Receptor
ConclusionThe simple GR-PR predictor proposed in this study seems to be at least as accurate as more complex tools and should be the preferred tool for the prediction of Oncotype Dx RS from clinicopathologic parameters when the Oncotype Dx test is not available. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - February 20, 2019 Category: Cancer & Oncology Source Type: research

Physical therapy pathway and protocol for patients undergoing hematopoietic stem cell transplantation: Recommendations from The Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) Group
Publication date: Available online 11 January 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Jaleel Mohammed, Mahmoud Aljurf, Abdulaziz Althumayri, Muntaha Almansour, Ahmed Alghamdi, Amir Ali Hamidieh, Alaa ElHaddad, Tarek Ben Othman, Ali Bazarbachi, Fahad Almohareb, Mohsen Alzahrani, Salam S. Alkindi, Fahad Alsharif, Waleed Da'na, Hani Alhashmi, Mohamed A. Bekadja, Salem H. Al-Shammari, Asma El Quessar, Tariq M. Satti, Naif AljohaniAbstractPatients undergoing hematopoietic stem cell transplantation (HSCT) are often referred for physical therapy (PT) to help improve their quality of life. However, to our k...
Source: Hematology Oncology and Stem Cell Therapy - January 15, 2019 Category: Cancer & Oncology Source Type: research

“Physical Therapy Pathway and Protocol for patients undergoing hematopoietic stem cell transplantation: Recommendations from The Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) Group”
Publication date: Available online 11 January 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Jaleel Mohammed, Mahmoud Aljurf, Abdulaziz Althumayri, Muntaha Almansour, Ahmed Alghamdi, Amir Ali Hamidieh, Alaa ElHaddad, Tarek Ben Othman, Ali Bazarbachi, Fahad Almohareb, Mohsen Alzahrani, Salam S. Alkindi, Fahad Alsharif, Waleed Da'na, Hani Alhashmi, Mohamed A. Bekadja, Salem H. Al-Shammari, Asma El Quessar, Tariq M. Satti, Naif AljohaniAbstractPatients undergoing HSCT are often referred for physical therapy (PT) to help improve their quality of life. However, to our knowledge there is no clear PT pathway to g...
Source: Hematology Oncology and Stem Cell Therapy - January 11, 2019 Category: Cancer & Oncology Source Type: research

The Strange Case of Dr. Hashmi and Mr. Hyde
Publication date: Available online 9 January 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Shahrukh K. Hashmi (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - January 10, 2019 Category: Cancer & Oncology Source Type: research

Low-dose Radiotherapy for Extranodal Marginal Zone B Lymphoma of the Lip: Case Report and Literature Review
We present a case report of a patient with extranodal NHL of the lip treated with chemotherapy and low-dose radiation treatment (RT). The patient was affected by B-cell NHL of the marginal zone, Stage IAE. After a few months of observation with this progressive disease, the patient was submitted to two cycles of chemotherapy with no response. Therefore, he was treated with very low-dose RT consisting of two fractions of 2 Gy. Complete response was observed and after 1-year follow-up, persistent complete response was recorded. In cases of localized disease, especially in patients with comorbidities of poor performance statu...
Source: Hematology Oncology and Stem Cell Therapy - January 1, 2019 Category: Cancer & Oncology Source Type: research

A Single-institution Experience of Performing Bloodless Transplant in Jehovah's Witness Patients
Publication date: Available online 27 December 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Alexander Coltoff, Aditya Shreenivas, Solmaz Afshar, Amir SteinbergAbstractAutologous stem cell transplant has been shown to prolong survival in multiple myeloma (MM). A common complication of the pre-transplant conditioning chemotherapy is severe multi-lineage cytopenias, resulting in significant transfusion requirements. Jehovah's Witnesses are members of a religious group that do not accept the transfusion of blood products. Many large transplant centers refuse to perform transplantation in Jehovah's Witnesses ...
Source: Hematology Oncology and Stem Cell Therapy - December 28, 2018 Category: Cancer & Oncology Source Type: research

Epstein-Barr Viremia and Post-Transplant Lymphoproliferative Disorders in patients undergoing Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide
Publication date: Available online 9 December 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Ghulam Rehman Mohyuddin, John Roller, Leyla Shune, Tara Lin, Ajoy Dias, Siddhartha Ganguly, Sunil Abhyankar, Joseph McGuirk, Anurag Singh (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - December 10, 2018 Category: Cancer & Oncology Source Type: research

Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patient Aged Older Than 76 Years with Refractory Acute Myeloid Leukemia
Publication date: Available online 9 December 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Jean El-Cheikh, Rana Salem, Radwan Massoud, Charelle Salem, Nohra Ghaoui, Souha S. Kanj, Rami Mahfouz, Ali Bazarbachi (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - December 10, 2018 Category: Cancer & Oncology Source Type: research

Impact of Hospital Hospitality House Programs on Quality of Life and Mood of Patients and Caregivers after Hematopoietic Stem Cell Transplant
ConclusionEfforts to improve QOL30 of HSCT patients and caregivers in the confined environment of an HHH should focus on patients with low baseline QOL and older patients. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - December 10, 2018 Category: Cancer & Oncology Source Type: research

Ki-67 Labeling Index in Glioblastoma; Does it Really Matter?
ConclusionThe difference between the survival curves of patients with Ki-67 labeling index of ≤ 27%, and Ki-67 of> 27% was statistically insignificant (p = .130). Therefore, Ki-67 labeling index alone cannot predict survival in glioblastoma patients. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - December 8, 2018 Category: Cancer & Oncology Source Type: research

Impact of CD39 Expression on CD4+ T Lymphocytes and 6q Deletion on Outcome of Patients With Chronic Lymphocytic Leukemia
Publication date: Available online 11 October 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Eman Mosaad Zaki, Asmaa Mohamed Zahran, Alshimaa Abdelazeem Metwaly, Rania Hafez, Safinaz Hussein, Abdallah Elaiw MohammedAbstractObjective/BackgroundChronic lymphocytic leukemia is one of the commonest leukemias affecting adults. CD39 inhibits T-cell and NK cell responses by hydrolyzing adenosine triphosphate and adenosine diphosphate, suppressing the immune system. We investigated expression of CD39 on CD4+ T Lymphocytes in chronic lymphocytic leukemia (CLL) patients and its relationship with deletion 6q, its ass...
Source: Hematology Oncology and Stem Cell Therapy - October 13, 2018 Category: Cancer & Oncology Source Type: research

Cutaneous light chain amyloidosis with multiple myeloma: A concise review
ConclusionsWe reviewed the constellation of the cutaneous manifestations of AL amyloidosis with concurrent MM. We found a female predominance, and more than half presented as hemorrhagic bullous lesions. There is a preponderance of λ light chains over kappa (κ) light chains, both as a free light chain (15% vs. 4%) and as an intact Ig (38% vs. 24%; absolute number of 14 vs. 7 patients, respectively). In the subgroup of patients with bullous skin lesions, λ light chain was present in eight cases and κ light chain in seven cases. All κ light chain subtypes presented with bullous lesions and no ...
Source: Hematology Oncology and Stem Cell Therapy - October 5, 2018 Category: Cancer & Oncology Source Type: research

Early posttraumatic changes in coagulation and fibrinolysis systems in isolated severe traumatic brain injury patients and its influence on immediate outcome
ConclusionIncidence of TIC in iSTBI is 41.6%, with 4.7 times odds for mortality. Traumatic brain injury causes enhanced coagulation activation, inadequate inhibition, exacerbation of thrombin generation, and subsequent increased fibrinolysis. ROC curve analysis revealed a cut-off of PS ≤ 74 with specificity 63.8%, sensitivity 72.7% for development of TIC. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 5, 2018 Category: Cancer & Oncology Source Type: research

Durable remission of a patient with primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
Publication date: Available online 28 September 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Shaima M. Al Aoun, Shahid Iqbal, Tahani M. AlHalouli, Syed Z. Zaidi, Ibraheem H. MotabiAbstractPrimary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (CD8+ PCAETL) is a rare disease characterized by aggressive clinical course and short survival. All available data are extracted from case reports and case series. The outcome is dismal and only two reported cases were cured after several lines of therapies including stem cell transplant. We herein present the case of a patient with CD8+ PCAETL w...
Source: Hematology Oncology and Stem Cell Therapy - October 5, 2018 Category: Cancer & Oncology Source Type: research

Cutaneous Amyloidosis Light-Chain Amyloidosis With Multiple Myeloma: A Concise Review
ConclusionsWe reviewed the constellation of the cutaneous manifestations of AL amyloidosis with concurrent MM. We found a female predominance, and more than half presented as hemorrhagic bullous lesions. There is a preponderance of λ light chains over kappa (κ) light chains, both as a free light chain (15% vs. 4%) and as an intact Ig (38% vs. 24%; absolute number of 14 vs. 7 patients, respectively). In the subgroup of patients with bullous skin lesions, λ light chain was present in eight cases and κ light chain in seven cases. All κ light chain subtypes presented with bullous lesions and no ...
Source: Hematology Oncology and Stem Cell Therapy - September 22, 2018 Category: Cancer & Oncology Source Type: research

Clinical and Histopathological Spectrum of Toxic Erythema of Chemotherapy in Patients Who Have Undergone Allogenic Hematopoietic Cell Transplantation
ConclusionThe diagnosis of TEC should be considered after a correlation of clinical and histological findings in conjunction with a timeline of chemotherapy administration. TEC is a clinical diagnosis that is supported by pathological confirmation. Suggested criteria for the diagnosis of TEC may be helpful to dermatologists and clinicians when caring for these patients. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - September 21, 2018 Category: Cancer & Oncology Source Type: research

Vitamin D Deficiency and Graft-Versus-Host Disease in Hematopoietic Stem Cell Transplant Population
Publication date: Available online 8 September 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Abeer ArainAbstractVitamins are the organic compounds that have long been known to play a significant role in our body by functioning as hormones and antioxidants. Vitamin D, a fat-soluble vitamin, is the main regulator of calcium hemostasis in our body. At the same time, it is also known to show its potential effects on the immune system by modulating the differentiation, activation, and proliferation of T and B lymphocytes. The immunomodulatory properties of vitamin D are also known to have a crucial role in the...
Source: Hematology Oncology and Stem Cell Therapy - September 9, 2018 Category: Cancer & Oncology Source Type: research

Combined Haploidentical and Umbilical Cord Blood Transplantation for Severe Aplastic Anemia: Unique Hematopoietic Reconstitution
Publication date: Available online 29 August 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Anant Vatsayan, Hasan Hashem, Kristen Nagle, Linda Cabral, Hillard Lazarus, Jignesh DalalAbstractHematopoietic stem cell transplant (HSCT) with matched sibling donor (MSD) is considered the first line of therapy for patients with severe aplastic anemia (SAA) who are
Source: Hematology Oncology and Stem Cell Therapy - August 31, 2018 Category: Cancer & Oncology Source Type: research